OBJECTIVES: Three target therapies for advance CRC had been approved by TFDA since 2005; only two are under reimbursement now. Long reimbursement process had prevented advanced CRC patients from prescribing target therapy. This study is to use Cetuximab, the first reimbursed target therapy to evaluate the impact of time gap from TFDA approval to reimbursement on mortality for advanced CRC patients. METHODS: The data was form 2 million sampling reimbursement data set of Taiwan’s National Health Insurance Research Database (NHIRD) and diseased stage was derived from the Taiwan Cancer Registry (TCR) between 2007 and 2011. Diseased stage diagnosed for the first time ever of CRC patients was recorded in TCR. Patients’ survival data and prescription time of target therapy were derived. Fisher exact test was used for the comparisons of frequencies; log rank was used survival comparisons; and hazard ratio was derived using both Cox regression with time and time independent analysis.  RESULTS: